Últimas noticias sobre Kazia Therapeutics (NASDAQ:KZIA) Bolsa

Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics Ltd

Analysts' ratings for Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) over the last quarter vary from bullish to bearish, as provided by 50 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">26</td>
<td align="right">23</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">17</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $244.48, a high estimate of $290.00, and a low estimate of $197.00. This upward trend is evident, with the current average reflecting a 6.12% increase from the previous average price target of $230.38.
<img src="https://www.benzinga.com/files/images/story/2024/1734724858_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Amazon.com. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Andrew Quail</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Michael Morton</td>
<td>MoffettNathanson</td>
<td>Raises</td>
<td>Buy</td>
<td>$248.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Alex Haissl</td>
<td>Redburn Atlantic</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$197.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Tom Forte</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Lee Horowitz</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$232.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$246.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$285.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$236.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$223.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$245.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Wlodarczak</td>
<td>Pivotal Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$260.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amazon.com. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amazon.com compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amazon.com's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AMZN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amazon.com analyst ratings.</a>
<h2>Unveiling the Story Behind Amazon.com</h2>
Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 75% of total, followed by Amazon Web Services' cloud computing, storage, database, and other offerings (15%), advertising services (5% to 10%), and other the remainder. International segments constitute 25% to 30% of Amazon's non-AWS sales, led by Germany, the United Kingdom, and Japan.
<h3>Unraveling the Financial Story of Amazon.com</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Amazon.com's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.04%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Amazon.com's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.65%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Amazon.com's ROE excels beyond industry benchmarks, reaching 6.19%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Amazon.com's ROA excels beyond industry benchmarks, reaching 2.69%. This signifies efficient management of assets and strong financial health.
Debt Management: Amazon.com's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.52.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

AMZN

50 Analysts Assess Amazon.com: What You Need To Know

9 analysts have expressed a variety of opinions on Interactive Brokers Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $176.78, a high estimate of $214.00, and a low estimate of $163.00. Surpassing the previous average price target of $156.78, the current average has increased by 12.76%.
<img src="https://www.benzinga.com/files/images/story/2024/1734724850_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Interactive Brokers Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$190.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$214.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Daniel Fannon</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$152.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Interactive Brokers Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Interactive Brokers Gr compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Interactive Brokers Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Interactive Brokers Gr's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IBKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Interactive Brokers Gr analyst ratings.</a>
<h2>Unveiling the Story Behind Interactive Brokers Gr</h2>
Interactive Brokers is an online brokerage that generates trading commissions (around 31% of net revenue) from facilitating trading in a wide range of products, including equity, options, futures, foreign exchange, bonds, mutual funds, and exchange-traded funds. Interactive Brokers also generates net interest income (about 64% of net revenue) from idle client cash and earns fees (about 6% of net revenue) from ancillary services. Principal trading and other miscellaneous activities are small (about 5% of net revenue). The firm derives about 70% of its net revenue from the US and 30% from international markets.
<h3>Interactive Brokers Gr's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Interactive Brokers Gr showcased positive performance, achieving a revenue growth rate of 18.1% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 7.68%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Interactive Brokers Gr's ROE stands out, surpassing industry averages. With an impressive ROE of 4.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Interactive Brokers Gr's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.13%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Interactive Brokers Gr's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IBKR

Analyst Expectations For Interactive Brokers Gr's Future

11 analysts have shared their evaluations of Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $106.36, along with a high estimate of $117.00 and a low estimate of $96.00. Experiencing a 1.43% decline, the current average is now lower than the previous average price target of $107.90. 
<img src="https://www.benzinga.com/files/images/story/2024/1734724838_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Popular is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$104.00</td>
<td>-</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$116.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$98.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Frank Schiraldi</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$104.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Popular. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Popular compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Popular's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Popular's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BPOP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Popular analyst ratings.</a>
<h2>Discovering Popular: A Closer Look</h2>
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
<h3>Unraveling the Financial Story of Popular</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Popular's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 7.1%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Popular's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 22.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Popular's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.79% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Popular's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.21%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Popular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.18.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPOP

Deep Dive Into Popular Stock: Analyst Perspectives (11 Ratings)

Ratings for Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $112.75, a high estimate of $130.00, and a low estimate of $78.00. A decline of 7.96% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1734724828_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Innovative Ind Props. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merrill Ross</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Aaron Grey</td>
<td>Alliance Global Partners</td>
<td>Announces</td>
<td>Buy</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$118.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Merrill Ross</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$125.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Innovative Ind Props. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Innovative Ind Props compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Innovative Ind Props's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Innovative Ind Props's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IIPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Innovative Ind Props analyst ratings.</a>
<h2>About Innovative Ind Props</h2>
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
<h3>Financial Milestones: Innovative Ind Props's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Innovative Ind Props faced challenges, resulting in a decline of approximately -1.67% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 51.07%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Innovative Ind Props's ROE stands out, surpassing industry averages. With an impressive ROE of 2.03%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Innovative Ind Props's ROA stands out, surpassing industry averages. With an impressive ROA of 1.64%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.15.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IIPR

Assessing Innovative Ind Props: Insights From 4 Financial Analysts

In the preceding three months, 6 analysts have released ratings for Pagaya Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Pagaya Techs, presenting an average target of $22.83, a high estimate of $36.00, and a low estimate of $11.00. This current average has decreased by 35.14% from the previous average price target of $35.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1734724820_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Pagaya Techs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rayna Kumar</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Michael Legg</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pagaya Techs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Pagaya Techs compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pagaya Techs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pagaya Techs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PGY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pagaya Techs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Pagaya Techs's Background</h2>
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, big data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
<h3>Pagaya Techs's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Pagaya Techs showcased positive performance, achieving a revenue growth rate of 23.75% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Pagaya Techs's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -27.07%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Pagaya Techs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -13.66%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Pagaya Techs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.78%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.49, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Pagaya Techs's Future

Did a series of unfortunate events cause funnyman Jim Carrey to finally sell his LA home of 30 years by taking a drop of $10 million from his original asking price? The 10,954-square-foot house in Brentwood went into contract with an asking price of $19.75 million, down from $28.9 million a year ago.&nbsp;
<h2 class="wp-block-heading">Claims To Need Cash</h2>
Carrey had stated in 2022 that he was quitting acting after starring in the <a href="https://www.benzinga.com/general/entertainment/24/04/38174401/paramount-aims-for-sonic-movies-to-reach-avengers-level-status-says-producer">wildly successful</a> &#8220;Sonic the Hedgehog 2,&#8221; but his time off was short-lived. The actor stars in the third installment, which will be released on December 20th. When questioned about the retirement U-turn during the film&#8217;s promotion, Carrey hinted at a cash crunch:
Don't Miss:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=unlockboost-yahoo"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>
&#8220;I came back to this universe because I get to play a genius, which is a bit of a stretch,&#8221;<a href="https://x.com/APEntertainment/status/1866579281045811233?mod=article_inline"> Carrey quipped</a>. &#8220;And you know, <a href="https://www.benzinga.com/news/24/12/42512179/i-bought-a-lot-of-stuff-jim-carrey-admits-joining-other-stars-returning-to-acting-due-to-money-woes-after-retirement">I bought a lot of stuff</a> and I need the money, frankly.&#8221;
The actor, 62, is reported to have a net worth of $180 million. He previously sold a Malibu home for $13.95 million in 2013 and also owns a home in Maui, which is believed to have been purchased in 2017. It is his primary residence. According to Celebrity Net Worth, Carrey also owns an apartment in New York.
Carrey previously told the New York Post of his recently sold LA home:
&#8220;For three decades, it&#8217;s been a sanctuary for me, but I don&#8217;t spend a lot of time there now and I want someone else to enjoy it like I have.&#8221; Carrey still stands to make a fortune by most people&#8217;s standards from selling his LA home, having purchased it way back in 1994 for $3.8 million.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">Nineties Heyday</h2>
Carrey&#8217;s career heyday was during the nineties and early oughts when he was the first actor to earn $20 million for a movie and earned at least $300 million from film salaries and bonuses. Box office hits from that era include The Mask, Dumb and Dumber, The Truman Show, Liar Liar and Bruce Almighty. Despite big up front checks, Carrey also made some savvy financial moves. At the height of his fame, he relinquished a big front-end paycheck for the movie &#8220;Yes Man&#8221; in exchange for being a part owner of the movie. It paid off as the film grossed $223 million worldwide, earning Carrey around $30 million.
Carrey&#8217;s recent return to the big screen comes after a significant downturn in his creative output. He has acted in only a handful of films in the last few years, including Sonic the Hedgehog 3, his only film of 2024. According to the Daily Mail, Carrey&#8217;s luxury car collection and global travel have helped him take a bite out of his fortune, which, coupled with his sporadic film work, has caused his net worth to drop. He wouldn't be the first Hollywood star to fall victim to <a href="https://www.benzinga.com/personal-finance/24/10/41418807/al-pacino-went-broke-after-blowing-50-million-on-16-cars-23-cellphones-and-400k-for-landscaping-">profligate luxury car spending</a>.
Trending: <a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.<a href="https://www.benzinga.com/go/arrived-private-credit-yf">&nbsp;</a>
<h2 class="wp-block-heading">A More Meaningful Life</h2>
Carrey&#8217;s decision to step away from Hollywood at 62 may have been motivated by a natural desire to lead a more meaningful life away from the entertainment business.
&#8220;I really like my quiet life and I really like putting paint on canvas and I really love my spiritual life and I feel like – and this is something you might never hear another celebrity say as long as time exists – I have enough. I&#8217;ve done enough. I am enough.&#8221;
Clearly, something changed.
Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today.<a href="https://smartasset.com/retirement/find-a-financial-planner?utm_source=benzinga&amp;utm_campaign=ben&amp;utm_content=y2_5MilNestEgg"> SmartAsset&#8217;s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost</a> to decide which one is right for you.
<h2 class="wp-block-heading">Interest Rates Are Falling, But These Yields Aren't Going Anywhere</h2>
Lower interest rates mean some investments won't yield what they did in months past, but you don't have to lose those gains. Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities.
<a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate. The best part? Unlike other private credit funds, <a href="https://www.benzinga.com/go/arrived-private-credit-yf">this one has a minimum investment of only $100.&nbsp;</a>
Looking for fractional real estate investment opportunities? The <a href="https://www.benzinga.com/alternative-investments/real-estate">Benzinga Real Estate Screener</a> features the latest offerings.

Real Estate

No Laughing Matter: Jim Carrey Sells LA Home of 30 Years After $10M Price Drop Amid Claims He Needs The Money

Across the recent three months, 4 analysts have shared their insights on Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $45.0, a high estimate of $50.00, and a low estimate of $41.00. No alteration is observed as the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1734724811_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Vital Farms. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Des Lauiers</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Rob Dickerson</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Brian Holland</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Vital Farms. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Vital Farms compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Vital Farms's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Vital Farms's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VITL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vital Farms analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Vital Farms</h2>
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter &amp; Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
<h3>Vital Farms's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Vital Farms's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 31.31%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Vital Farms's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.14%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Vital Farms's ROE excels beyond industry benchmarks, reaching 3.03%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Vital Farms's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.24%, the company showcases efficient use of assets and strong financial health.
Debt Management: Vital Farms's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VITL

What 4 Analyst Ratings Have To Say About Vital Farms

U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 600 points on Friday.
The Dow traded up 1.55% to 43,000.53 while the NASDAQ rose 1.65% to 19,693.06. The S&amp;P 500 also rose, gaining, 1.53% to 5,956.61.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a>
Leading and Lagging Sectors Real estate shares jumped by 2.4% on Friday.
In trading on Friday, consumer staples shares rose by just 0.4%.
Top Headline
The total number of active U.S. oil rigs climbed by 1 to 483 rigs this week, Baker Hughes Inc reported.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares shot up 40% to $4.8500 after the company announced FDA approval for SYMVESS for treating extremity vascular injuries. HC Wainwright &amp; Co. raised its price target on the stock from $12 to $15.</li>
<li>Shares of Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>)got a boost, surging 25% to $6.55 after the company and Moderna recently announced a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157. The company also announced an investment from Merck.</li>
<li>Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares were also up, gaining 37% to $0.4349 after the company announced it received an additional 180 calendar days for compliance with the Nasdaq minimum bid price requirement.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 74% to $0.4276 as the company reported the pricing of $20.0 million follow on offering.</li>
<li>Shares of Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) were down 54% to $0.9297 after the company announced top-line results of its NAVIGATE clinical trial and confirmed belapectin did not achieve statistical significance.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) was down, falling 17% to $85.72. The company announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE program.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $69.43 while gold traded up 1.5% at $2,648.30.
Silver traded up 2.7% to $30.210 on Friday, while copper rose 0.8% to $4.1075.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 0.88%, Germany's DAX fell 0.43% and France's CAC 40 declined 0.27%. Spain's IBEX 35 Index rose 0.24%, while London's FTSE 100 fell 0.26%.
Consumer confidence in the Eurozone declined by 0.8 points to a reading of -14.5 in December.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 0.29%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index declining 0.06% and India's BSE Sensex falling 1.49%.
Economics
<ul>
<li>The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, and versus a reading of 71.8 in November.</li>
<li>U.S. personal income increased by 0.3% month-over-month in November compared to a revised 0.7% gain in October.</li>
<li>Personal spending increased by 0.4% to an annualized rate of $20.2 trillion in November.</li>
<li>The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.</li>
<li>The total number of active U.S. oil rigs climbed by 1 to 483 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

GALT

HUMA

PSNL

TAOP

Dow Surges Over 600 Points, Gold Jumps 1.5%

WIIM

Jabil shares are trading higher after Barclays maintained an Overweight rating on the stock and raised its price target from $157 to $179.

HOOD

Robinhood Markets shares are trading higher after Keefe, Bruyette & Woods maintained a Market Perform rating on the stock and raised its price target from $24 to $38.

Risk sentiment returned to Wall Street on Friday, revitalized by softer-than-expected November inflation data leading to a strong market rebound following the selloff triggered by the <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42615908/feds-preferred-inflation-gauge-falls-more-than-expected-markets-breathe-sigh-of-relief">Federal Reserve&#8217;s recent meeting.</a>
The Personal Consumption Expenditure price index rose 2.4% year-over-year in November, falling short of the 2.5% increase forecasted. The core PCE, a key gauge closely watched by the Fed, also missed expectations, rising 2.8% compared to the anticipated 2.9%.
By midday Friday, all major indices were in rally mode, with broad-based gains across sectors. In the S&amp;P 500, 480 companies traded higher, and every sector advanced as investors welcomed the reprieve in inflationary pressures.
The real estate sector led the charge, rebounding sharply after being hit hardest in the aftermath of the Fed meeting. Small-cap stocks in the Russell 2000 also posted robust gains, powered by a strong recovery in regional banks.
The travel industry soared, driven by upbeat earnings and optimistic guidance from Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>), which fueled enthusiasm across the sector. The cruise line rose by 6%, eyeing the highest close since October 2021. 
In the bond market, yields dropped by approximately 5 basis points across the curve, boosting Treasury prices. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) gained nearly 1%, recovering some ground after a 3% slide over the previous two sessions. The dollar softened, declining 0.6%, while gold gained over 1%. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) attracted dip buyers after plunging to $92,118. Although the cryptocurrency pared its daily losses, it remains on track for its worst weekly performance in four months.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,853.53</td>
<td>1.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,934.51</td>
<td>1.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,246.04</td>
<td>1.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,339.90</td>
<td>1.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.1% to $592.31.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.2% to $429.61.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 1.4% higher to $521.53.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 1.2% to $222.59.</li>
<li>The&nbsp;Real Estate Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up by 2.3%; the&nbsp;Consumer Staples Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, up 0.6%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<ul>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) plummeted 17%, marking its worst single-day drop since April 2002. after disappointing weight-loss trial data for<a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss"> its obesity drug, CagriSema.</a></li>
<li>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) rallied over 8% as analysts at OTR Research raised the stock rating from Negative to Mixed.</li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) also rallied over 6% in reaction to Carnival Cruise&#8217;s upbeat results. Other travel-related companies seeing strong gains Friday included Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), up 3.9%, Hyatt Hotels Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>), up 3.4%, and Royal Caribbean Cruise Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), up 3.6%.</li>
<li>Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) fell 1.2% in reaction to its latest quarterly results and FedEx Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) inched 0.6% higher. </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss">EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Travel

Treasuries

Econ #s

Economics

ETFs

$BTC

ABNB

SPDR Dow Jones Industrial Average ETF Trust

ENPH

NCLH

iShares Trust Barclays 20+ Year Treasury Bond Fund

XLRE

Wall Street Rallies On Soft Inflation Data, Bonds Rebound, Travel Stocks Surge: What's Driving Markets Friday?

TD Synnex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) short percent of float has risen 24.38% since its last report. The company recently reported that it has 2.00 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TD Synnex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TD Synnex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing TD Synnex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TD Synnex's peer group average for short interest as a percentage of float is 4.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into TD Synnex's Recent Short Interest

GoPro's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRO#NYSE">GPRO</a>) short percent of float has risen 24.92% since its last report. The company recently reported that it has 5.07 million shares sold short, which is 4.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.47 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>GoPro Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723917_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GoPro has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing GoPro's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, GoPro's peer group average for short interest as a percentage of float is 4.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

GPRO

Peering Into GoPro's Recent Short Interest

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has fallen 4.18% since its last report. The company recently reported that it has 39.78 million shares sold short, which is 30.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 14.45%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NVAX

Peering Into Novavax's Recent Short Interest

AFRM

Affirm Holdings shares are trading higher after JMP Securities upgraded the stock from Market Perform to Market Outperform while maintaining its price target at $78.

<a href="https://www.usitc.gov/press_room/news_release/2024/er1220_66270.htm" title="https://www.usitc.gov/press_room/news_release/2024/er1220_66270.htm">https://www.usitc.gov/press_room/news_release/2024/er1220_66270.htm</a>

DELL

USITC Institutes Section 337 Investigation Of Certain Wireless Communication Devices And Components Thereof; Probe Certain Smart TVs Made By Dell, HP, Lenovo After Request By International Semiconductor Group Co

On Friday,&nbsp;Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released headline results from the REDEFINE 1 Phase 3 trial in the&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">global REDEFINE program</a>.
When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.
In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th" rel="noreferrer noopener">added side effects</a>.
William Blair points out that Novo Nordisk didn&#8217;t provide detailed tolerability data in its press release, making it hard to compare their treatment with Eli Lilly&#8217;s Zepbound directly. However, only 57% of patients could increase their dose to the highest level with CagriSema, compared to 83% with cagrilintide and 70% with Wegovy, suggesting that CagriSema may have a tougher tolerability profile.
The analyst writes the tolerability issue is a key reason why investors are concerned about the REDEFINE 1 trial. The analyst <a href="https://www.benzinga.com/quote/amgn/analyst-ratings" target="_blank" rel="noreferrer noopener">rates the shares Outperform</a>.
The results from CagriSema are also beneficial for Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), which recently showed that its GLP-1R agonist/GIPR antagonist, MariTide, leads to effective <a target="_blank" href="https://www.benzinga.com/24/11/42189129/amgen-reveals-data-from-closely-watched-monthly-obesity-drug-with-weight-loss-of-up-to-20-at-one-year-and-no-plateau" rel="noreferrer noopener">weight loss in Phase 2 trials.</a>
MariTide&#8217;s weight loss of about 20% after 52 weeks (or 18% at the 420 mg dose) is similar to or slightly below the weight loss seen with other GLP-1 therapies, such as CagriSema and Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41950871/amgen-defends-its-investigational-monthly-weight-loss-injection-after-analyst-cites-maritides-impact-on-bone-density" rel="noreferrer noopener">Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide&#8217;s Impact on Bone Density</a>
The analyst writes that MariTide&#8217;s advantage could lie in its less frequent monthly dosing, which may stand out in the obesity market.
Additionally, the way MariTide is dosed appears to reduce gastrointestinal side effects with the first dose, suggesting it may have a more tolerable long-term profile and improve patient adherence.
Price Action: AMGN stock is up 1.58% at $265.33 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42621868/nvidia-secures-eu-approval-for-runai-deal-us-probes-china-export-breach" target="_blank" rel="noreferrer noopener">Nvidia Secures EU Approval For Run:ai Deal, US Probes China Export Breach</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Biotech

Large Cap

Health Care

Movers

General

AMGN

What's Going On With Amgen Stock On Friday?

Legal

NPSCY

Nippon Steel, U.S. Steel Allege White House Has Had 'Impermissible Influence' Over CFIUS Review Of Proposed Tie-Up-Letter; White House Denies Allegations Of Undue Influence; Nippon Steel, U.S. Steel Vow To Challenge An Expected Block Of The Deal In U.S. Court As A Violation Of Due Process And Authority Of The President Under CFIUS Rules-Letter

Value stocks are having a rough go in 2024, at least compared to broader stock indexes.
The benchmark S&amp;P Value Index is up 10.46% on a year-to-date basis. That's well below the S&amp;P 500, which has generated 23.8% returns over the same time period. The index is also well below the year-to-date performance of the S&amp;P Growth Index, which stands at 35.11% as of December 20.
Yet as the calendar flips to 2025, value stocks seem to be in a decent position.
Here&#8217;s three reasons why value stocks may be a good bet for 2025.
"Inflation is moderating, and the economy seems to be steadying," says Jason Hishmeh, co-founder at Varyence, a technology firm that works with startup companies to grow their business. "That's great news for sectors like manufacturing, financials, and energy, which tend to perform well in this environment. Companies with strong fundamentals—low price-to-earnings ratios and steady earnings growth—look particularly attractive."
Other market experts say Main Street investors need to get a good grip on what value stocks really represent.
"Value stocks are a group of underappreciated and ignored stocks that are worth more than their fundamentals would suggest," says Stephen Callahan, trading behavior analyst at Firstrade. "This is a market driven by momentum. As a value investor, valuations are never a reason to own something. Fundamentals are the reason why you own something. We need to match those two things up." What's more, not all cheap stocks are value stocks.
"Some stocks are cheap for quantifiable reasons, such as poor earnings," Callahan says. "Value stocks are good companies at low prices. They are financially stable, have high-profit margins, low debt-to-income ratio, strong earnings, and while not mandatory, a good sign is that they pay dividends."
Value stocks have several trends pointing upward heading into a new year. Market experts point to these largest 2025 impactors.
<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-holiday-24/?t=be16bespmirebz36&amp;utm_source=WebRD-1219">[65% Off Benzinga Edge – Sale Ends December 31!]</a>
Back in business under Trump. President-elect Donald Trump said he'd prioritize a business-friendly agenda in his campaign stump speeches, which would be good news for value stocks.
"Trump spoke frequently about reducing the government deficit, lowering energy costs through increased domestic drilling, and implementing potentially looser regulations," says Ronen Cojocaru, CEO at San Francisco-based 8081.io, a fintech company that simplifies and automates digital asset trading. "Additionally, the prospect of corporate-friendly tax reforms could enhance profitability, making value stocks more attractive to investors."
Key expectations coming from the Trump camp include reduced regulations in sectors such as energy, financials, crypto, and industrials, which could lower compliance costs and increase profitability.
"Additionally, corporate-friendly tax reforms may enhance earnings, while a focus on domestic production and energy independence could create new opportunities for growth in the energy and manufacturing sectors," Cojocaru says. "But we should all look carefully at how Trump administration tariffs will take place, which can play a significant role in that space."
Large-cap value stocks to shine. In early December, BofA analysts projected the U.S. gross domestic product would rise by 2.4%, well ahead of other analyst projections that landed in the 2.0% range. Economists say that any GDP above 2% is good news for well-run, long-established companies that turn a profit.
So-called "GDP-sensitive" companies should benefit from a growing U.S. economy. &#8220;We see more opportunities in stocks than the index,&#8221; notes BofA head of U.S. equity and quantitative strategy Savita Subramanian in a recent research note, which pegged the S&amp;P 500 at a 6,666 target price for 2025. &#8220;In particular, we like companies with healthy cash return prospects and a tether to the US economy: large-cap value stocks.&#8221;
Cojocaru says large-cap value stocks are well-positioned to perform strongly in 2025, especially if the trends highlighted by BofA analysts continue to shape the market.
"Companies in this sector demonstrated remarkable resilience in 2024, navigating a high-inflation environment by adopting strict cost controls, improving operational efficiency, and managing capital strategically," he notes. "These actions now yield significant benefits as inflation moderates and interest rates show signs of stabilizing or potentially declining."
An upward trending economy. With analysts calling for a healthy US economy, a strong labor market, moderating inflation, and the resulting potential for further interest rate cuts, value stocks should rise accordingly.
"The economy is looking pretty solid right now, with strong jobs, inflation starting to settle, and maybe even some interest rate cuts on the horizon,"&nbsp; says Nick Scibilia, CEO of Orbit, a social media platform geared toward younger investors.&nbsp;
That scenario represents "awesome news" for value stocks, Scibilia notes. "People are spending more, businesses are booming, and that means more cash for those established companies," he says. "Plus, if interest rates drop, those steady dividend-paying value stocks will look even better."
Watch out for risks. Even with a generally rosy outlook on the sector, value investors should know various possible risks.
"Firstly, if inflation persists and interest rates continue to increase, value stocks could underperform," Scibilia says. "Secondly, a recession is still possible, and value stocks are not immune to economic downturns. Lastly, geopolitical uncertainty and global events could disrupt market conditions and negatively impact value stocks."
Still, Scibilia sees several sectors looking pretty hot right now.
"Energy has been a bit wild lately with prices bouncing around, but things are looking good long term," he notes. "Also, when the economy is humming, industrials are in high demand. Think infrastructure, manufacturing, transportation &#8211; they&#8217;re all key players in keeping things moving."
Additionally, robust economic fundamentals should help stocks across the board next year.
&#8220;A stronger economy is good for all solid companies, even ones that aren't considered value stocks right now," says Paul Gabrail, founder and host of the Everything Money YouTube channel. "The goal is to increase revenue and profit; over time, the stock price and value of the company will converge.&#8221;
Find the market's fastest-moving stocks and access real-time alerts, expert trade setups, and insider stock picks with Benzinga Edge. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-holiday-24/?t=be16bespmirebz36&amp;utm_source=WebRD-1219">Click here to take advantage of our End-of-Year Sale which ends December 31!</a>
Image via Pixabay

Opinion

3 Reasons to Buy Value Stocks Before January 1

RDDT

Reddit shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and a $210 price target.

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics has secured an exclusive worldwide license from QIMR Berghofer Medical Researc...

Kazia Therapeutics Advances Cancer Treatment Options

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics presented promising data from a Phase 1 trial of EVT801, showing potential as ...

Kazia Therapeutics Reveals Hopeful Ovarian Cancer Study

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics has unveiled encouraging Phase I study results at the ASTRO 2024, showing that...

Kazia Therapeutics Reveals Promising Brain Cancer Study

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics plans to modify the ratio of its American Depositary Shares (ADS) to improve i...

Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing

19:50 EDT Kazia Therapeutics (KZIA) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving break...

Kazia Therapeutics trading halted, news pending

These are the upcoming stock splits for the week of October 28 to November 1, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a cor...

Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics has announced a significant development in its quest to advance paxalisib, a p...

Kazia Therapeutics Advances Paxalisib with FDA Meeting

Meeting to be held on November 11-15 hosted by Maxim. Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...

Kazia Therapeutics management to meet with Maxim

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requireme...

Kazia Therapeutics Secures Nasdaq Compliance

Kazia Therapeutics ( ($KZIA) ) has provided an announcement. Kazia Therapeutics announced findings that highlight the potential of their lead produ...

Kazia Therapeutics Presents Promising Data on Paxalisib for Breast Cancer Treatment

ALBT

KZIA

MOVE

SVRE

Press Releases

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Biotech Experiences Strong Open Following Major Announcement

Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024

Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Small Cap

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Comments

Kazia Therapeutics

Noticias

Últimas noticias sobre Kazia Therapeutics (NASDAQ:KZIA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL